Hunsberger Holly C, Lee Seonjoo, Jin Michelle, Lanio Marcos, Whye Alicia, Cha Jiook, Scarlata Miranda, Matthews Louise C, Jayaseelan Keerthana, Denny Christine A
Division of Systems Neuroscience, Research Foundation for Mental Hygiene, Inc. (RFMH)/New York State Psychiatric Institute (NYSPI), New York, New York.
Department of Psychiatry, Columbia University Irving Medical Center (CUIMC), New York, New York; Mental Health Data Science, Research Foundation for Mental Hygiene, Inc. (RFMH)/New York State Psychiatric Institute (NYSPI), New York, New York.
Biol Psychiatry. 2025 May 1;97(9):900-914. doi: 10.1016/j.biopsych.2024.09.016. Epub 2024 Sep 28.
Neuropsychiatric symptoms, such as depression and anxiety, are observed in 90% of patients with Alzheimer's disease (AD), two-thirds of whom are women. Neuropsychiatric symptoms usually manifest long before AD onset creating a therapeutic opportunity. Here, we examined the impact of anxiety on AD progression and the underlying brainwide neuronal mechanisms.
To gain mechanistic insight into how anxiety affects AD progression, we performed a cross-sectional analysis on mood, cognition, and neural activity using the ArcCreER x eYFP (enhanced yellow fluorescent protein) x amyloid precursor protein/presenilin 1 (APP/PS1) (AD) mice. The Alzheimer's Disease Neuroimaging Initiative dataset was used to determine the impact of anxiety on AD progression in humans.
Female APP/PS1 mice exhibited anxiety-like behavior and cognitive decline at an earlier age than control mice and male mice. Brainwide analysis of c-Fos revealed changes in regional correlations and overall network connectivity in APP/PS1 mice. Sex-specific eYFP/c-Fos changes were observed; female APP/PS1 mice exhibited less eYFP/c-Fos cells in dorsal CA3, whereas male APP/PS1 mice exhibited less eYFP/c-Fos cells in the dorsal dentate gyrus. In the Alzheimer's Disease Neuroimaging Initiative dataset, anxiety predicted transition to dementia. Female participants positive for anxiety and amyloid transitioned more quickly to dementia than male participants.
While future studies are needed to understand whether anxiety is a predictor, a neuropsychiatric biomarker, or a comorbid symptom that occurs during disease onset, these results suggest that there are sex differences in AD network dysfunction and that personalized medicine may benefit male and female patients with AD rather than a one-size-fits-all approach.
神经精神症状,如抑郁和焦虑,在90%的阿尔茨海默病(AD)患者中都有出现,其中三分之二为女性。神经精神症状通常在AD发病前很久就已出现,这创造了一个治疗机会。在此,我们研究了焦虑对AD进展的影响以及潜在的全脑神经元机制。
为深入了解焦虑如何影响AD进展,我们使用ArcCreER x eYFP(增强型黄色荧光蛋白)x淀粉样前体蛋白/早老素1(APP/PS1)(AD)小鼠对情绪、认知和神经活动进行了横断面分析。阿尔茨海默病神经影像倡议数据集用于确定焦虑对人类AD进展的影响。
雌性APP/PS1小鼠比对照小鼠和雄性小鼠更早出现焦虑样行为和认知衰退。对c-Fos的全脑分析揭示了APP/PS1小鼠区域相关性和整体网络连接性的变化。观察到了性别特异性的eYFP/c-Fos变化;雌性APP/PS1小鼠在背侧CA3区的eYFP/c-Fos细胞较少,而雄性APP/PS1小鼠在背侧齿状回的eYFP/c-Fos细胞较少。在阿尔茨海默病神经影像倡议数据集中,焦虑预示着向痴呆的转变。焦虑和淀粉样蛋白呈阳性的女性参与者比男性参与者更快地转变为痴呆。
虽然需要进一步研究以了解焦虑是预测因素、神经精神生物标志物还是疾病发作时出现的共病症状,但这些结果表明AD网络功能障碍存在性别差异,个性化医疗可能使AD男性和女性患者受益,而非采用一刀切的方法。